Vivacelle Bio
PrivateLast Round
Series B
Feb 22, 2024
Total Funding Raised
$20.95M
Company Overview
Vivacelle Bio is a biotechnology company that develops nanoparticle-based resuscitation fluid therapies designed to treat septic shock and severe blood loss.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Medical Devices
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vivacelle Bio Comparables
Compare Vivacelle Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Adrenomed AG | 77% | |
| Matisse Pharmaceuticals | 75% | |
| Perfusion Medical | 74% |
Vivacelle Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 22, 2024 | ||||
| Grant | Sep 7, 2021 | ||||
| Grant | Nov 24, 2020 | ||||
| Series A | Jan 11, 2019 | ||||
| Seed | Sep 3, 2016 |
Key People
Founding team and executive leadership
Vivacelle Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NIH RADx | Grant, Seed |
| U.S. Department of War | Seed, Grant |
| 2Flo Ventures | Seed, Series A |
| Medical Technology Enterprise Consortium | Grant |
| U.S. Navy | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 17, 2026
Monthly visitors increased 50% MoM, reaching 1.2K.
- Jan 13, 2025
Attending BIO Partnering @ JPM Week 2025 in San Francisco.
Vivacelle Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Vivacelle Bio's valuation, stock price, and market status.
Is Vivacelle Bio a public or private company?
Vivacelle Bio is a private company.
What is the current stock price of Vivacelle Bio?
Vivacelle Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Vivacelle Bio worth (valuation)?
Valuation information for Vivacelle Bio is not publicly available.
Can I buy Vivacelle Bio stock?
Vivacelle Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Vivacelle Bio's last funding round?
Vivacelle Bio's most recent funding round was Series B on February 22, 2024.
Who are the main investors in Vivacelle Bio?
Key investors in Vivacelle Bio include NIH RADx, U.S. Department of War, 2Flo Ventures, Medical Technology Enterprise Consortium.
Will Vivacelle Bio IPO soon?
No public IPO plans have been announced for Vivacelle Bio.
How can I track Vivacelle Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Vivacelle Bio's secondary market activity and sign up for updates.